Neuroleptic Malignant Syndrome (NMS) is a life-threatening idiosyncratic reaction to dopamine antagonists (most commonly, but not always, antipsychotics) characterized by fever, altered mental status, muscle rigidity, and autonomic dysfunction.[1] It is hypothesized to be due to excessive dopamine receptor blockade. Certain individuals may be at a higher risk for NMS.
Neuroleptic malignant syndrome (NMS) must be diagnosed promptly to avoid serious injury or death, but there is no consensus on diagnostic criteria for this disorder. The 2011 International Consensus Study of Neuroleptic Malignant Syndrome Diagnostic Criteria proposed the following consensus criteria:[9]
2
measurements, measured orally)2
of the following:FEVERR
can be used to remember the clinical and laboratory features of NMS:F
- FeverE
- Encephalopathy (confusion, mental status changes)V
- Vital sign instability (tachycardia, tachypnea, and/or labile blood pressure)E
- Enzyme elevation (creatinine phosphokinase [CPK] increased because of rhabdomyolysis)R
- Rhabdomyolysis (caused by muscular rigidity distinguishes NMS from other toxidromes like serotonin syndrome and anticholinergic toxicity)R
- Rigidity Generalized “lead pipe” muscle rigidityNMS should be a diagnosis of exclusion and must be differentiated from other serious neurological or medical conditions, including central nervous system infections, inflammatory or autoimmune conditions, status epilepticus, subcortical structural lesions, and systemic conditions (e.g. - pheochromocytoma, thyrotoxicosis, tetanus, heat stroke).